RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES
Impact
The implications of S2863 on state laws and insurance practices are significant. It specifically amends existing regulations concerning health maintenance organizations and other medical service corporations to enhance the service delivery for hormone therapy. By setting a standard for the dispensing of medication, the bill seeks to reduce the administrative burden on patients and healthcare providers, potentially leading to better adherence to treatment protocols. This could be particularly beneficial for individuals on long-term hormone therapy, who may face challenges with frequent refills.
Summary
Bill S2863 is a legislative proposal aimed at modifying the coverage provisions of prescription hormone therapy under insurance policies in Rhode Island. The bill mandates that starting January 1, 2027, all individual and group health insurance plans that provide coverage for prescription hormone therapies must allow for the dispensing of up to twelve months' worth of medication in a single prescription. This is intended to improve access and streamline the healthcare process for individuals requiring hormone therapy, which is essential for various medical conditions.
Contention
Despite its well-intentioned goals, SB2863 may face opposition due to concerns about the management of controlled substances. The bill allows health plans to apply drug utilization management strategies, which could lead to limitations on the availability of certain medications based on insurance policies. Furthermore, by specifically excluding glucagon-like peptide-1 and related drugs from coverage, critics may argue that the bill does not sufficiently address all aspects of hormonal treatment.
Implementation
If passed, the bill will require significant adjustments within health systems and insurance providers to comply with the new prescription regulations. The process for healthcare providers may become more streamlined; however, additional guidelines and modifications may be necessary to ensure that the implementation is effective and does not inadvertently restrict access to necessary medications. The state will also need to address the implications for Medicaid beneficiaries, as provisions for hormone therapies will need to be in alignment with this bill.
Mandates all insurance contracts, plans or policies provide insurance coverage for the expense of diagnosing and treating infertility, for women between the ages of 25 and 42 years including preimplantation genetic diagnosis (PGD) in conjunction with IVF.
Removes the age restriction for benefits coverage and requires, for health insurance policies issued or renewed on or after January 1, 2026, that coverage must include reimbursement for applied behavior analysis provider services.
Requires individual and group health insurance policies that provide pregnancy-related benefits to cover medically necessary expenses for diagnosis and treatment of infertility and standard fertility-preservation services.
Requires health insurance plans to cover services provided by licensed certified professional midwives. Insurers must report utilization and cost data annually. Certain limited benefit policies are exempt.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.